Similar articles for PMID: 29707288

Year	Number of Results
2010	2
2012	5
2013	5
2014	9
2015	14
2016	8
2017	14
2018	12
2019	18
2020	14
2021	14
2022	8
2023	1
2024	0

1

Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations.

Salvador-Coloma C, Lorente D, Palanca S, Simarro J, Mancheño N, Sandoval J, Lahoz A, Juan Ó. Salvador-Coloma C, et al. J Thorac Dis. 2018 Mar;10(3):1386-1393. doi: 10.21037/jtd.2018.02.30. J Thorac Dis. 2018. PMID: 29707288 Free PMC article.

2

Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.

Medical Advisory Secretariat. Medical Advisory Secretariat. Ont Health Technol Assess Ser. 2010;10(24):1-48. Epub 2010 Dec 1. Ont Health Technol Assess Ser. 2010. PMID: 23074402 Free PMC article.

3

Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.

Chang GC, Tseng CH, Hsu KH, Yu CJ, Yang CT, Chen KC, Yang TY, Tseng JS, Liu CY, Liao WY, Hsia TC, Tu CY, Lin MC, Tsai YH, Hsieh MJ, Wu WS, Chen YM. Chang GC, et al. Lung Cancer. 2017 Feb;104:58-64. doi: 10.1016/j.lungcan.2016.12.002. Epub 2016 Dec 14. Lung Cancer. 2017. PMID: 28213001 Clinical Trial.

4

The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.

Lin JH, Lin D, Xu L, Wang Q, Hu HH, Xu HP, He ZY. Lin JH, et al. Oncotarget. 2017 Jan 10;8(2):3412-3421. doi: 10.18632/oncotarget.13787. Oncotarget. 2017. PMID: 27926500 Free PMC article.

5

Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study.

Chang JW, Hou MM, Hsieh JJ, Cheung YC, Wang HM, Chen JS, Wang CH, Chen CH, Yeh KY, Ou LY, Hsieh CH, Wu HD, Chen YT, Chang IC, Huang SF. Chang JW, et al. Biomed J. 2015 May-Jun;38(3):221-8. doi: 10.4103/2319-4170.138320. Biomed J. 2015. PMID: 25179728 Free article. Clinical Trial.

6

Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.

Yan X, Wang H, Li P, Zhang G, Zhang M, Yang J, Zhang X, Zheng X, Ma Z. Yan X, et al. Lung Cancer. 2019 Feb;128:6-12. doi: 10.1016/j.lungcan.2018.12.007. Epub 2018 Dec 6. Lung Cancer. 2019. PMID: 30642455

7

RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.

Yoshida T, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Ohe Y, Goto K. Yoshida T, et al. Lung Cancer. 2015 Dec;90(3):477-83. doi: 10.1016/j.lungcan.2015.09.025. Epub 2015 Oct 9. Lung Cancer. 2015. PMID: 26604031

8

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.

Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, Hatabu H, Rabin MS, Jänne PA, Johnson BE. Nishino M, et al. Lung Cancer. 2013 Mar;79(3):283-8. doi: 10.1016/j.lungcan.2012.11.007. Epub 2012 Dec 14. Lung Cancer. 2013. PMID: 23254265 Free PMC article. Clinical Trial.

9

Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI.

Lin L, Zhao J, Hu J, Huang F, Han J, He Y, Cao X. Lin L, et al. J Cancer. 2018 Jan 1;9(3):528-534. doi: 10.7150/jca.22378. eCollection 2018. J Cancer. 2018. PMID: 29483958 Free PMC article.

10

Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.

Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, Lee SH, Heo DS. Lee JK, et al. JAMA. 2014 Apr 9;311(14):1430-7. doi: 10.1001/jama.2014.3314. JAMA. 2014. PMID: 24715074

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

115 results

Results by year